From Health Canada:
Following discussions with Health Canada, Janssen-Ortho Inc. would like to update you on important new safety information pertaining to EVRA*. The EVRA* transdermal system marketed in Canada contains 6.0 mg norelgestromin (NGMN) and 0.60 mg ethinyl estradiol (EE) and is indicated for contraception.
For Health Professionals
For the Public
Wednesday, November 29, 2006
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment